Urologic Clinics of North America 2003: Vol 30 Index

25 Pages·2003·4.9 MB·English

UROLOGIC
CLINICS OF
NORTH AMERICA
Urol Clin N Am 30 (2003) 891-915
Cumulative Index
Volume 30
February UROLOGIC MANIFESTATIONS OF NEUROLOGIC DISEASE. pages 1-180
May LOCALIZED PROSTATE CANCER, pages 181-422
August CONTEMPORARY MANAGEMENT OF RENAL CELL CARCINOMA. pages 423-668
November FOLLOW-UP STRATEGIES AND MANAGEMENT OF RECURRENCE IN
UROLOGIC ONCOLOGY, pages 669-915
Note: Page numbers of article titles are in boldface type.
A fertility, 101-102
Aarskog syndrome, in children, 160 infections, 103-105
Kaposi's sarcoma, 102-103
Abscesses, prostatic, in AIDS, 104-105
lymphomas, 103
Acid-base abnormalities, after urinary tract nephrolithiasis, 99-100
reconstruction, for recurrent bladder prostate cancer, 103
cancer, 784 prostatic abscesses, 104-105
prostatitis, 104-105
Acupuncture, for prostate cancer, 374
renal cell carcinoma, 103
Acute renal failure, partial nephrectomy and, 536 squamous cell carcinoma, 103
vascular surgery and, 21-22 testicular atrophy, 101
testicular neoplasms, 103
Adenocarcinoma, prostatic. See Prostatic
voiding dysfunction, 100-101
adenocarcinoma.
Alcohol, as risk factor, for prostate cancer, 214
Adhesion molecules, as markers, for renal cell
carcinoma, 457-458 Allogeneic stem cell transplant, for metastatic
renal cell carcinoma, graft-versus-tumor
Adjuvant immunotherapy, for metastatic renal
response in, 618-620
cell carcinoma, 595
limitations of, 618
Adoptive immunotherapy, for metastatic renal rationale for, 613-615
cell carcinoma, 593-595 results of, 615, 617
toxicity of, 618
Adrenal androgen inhibitors, for prostate cancer,
for renal cell carcinoma, 611-622
after treatment failure, 409
rationale for, 612-613
Adrenal glands, involvement of, by renal cell
Alport’s syndrome, in children, 160
carcinoma, 469-470, 486
Aminoglutethimide, for prostate cancer, after
Adrenal insufficiency, tuberculosis and, 111
treatment failure, 409
Afferent pathways, in micturition, 27
Amputation, for squamous penile carcinoma,
AgNORS, as markers, for renal cell carcinoma, 857-858
491-492
Amygdalin, for prostate cancer, 372
AIDS, urologic complications of, 99-107
Anabolic steroids, and male infertility, 84
carcinoma in situ, 103
erectile dysfunction, 101 Androgel, for hypogonadism, 74-75
0094-0143/03/S - see front matter © 2003 Elsevier Inc. All rights reserved.
doi: 10.1016 S0094-0143(03)00078-8
892 Cumulative Index | Urol Clin N Am 30 (2003) 891-915
Androgen ablation therapy. for prostate cancer. Atherosclerosis. and renovascular
See Hormonal therapy. hypertension, 13
Androgen abnormalities, and erectile Atrophic carcinoma, of prostate, diagnosis of, 196
dysfunction. See Erectile dysfunction.
Atypical small acinar proliferation, clinical
and male infertility, 86-87, 147
significance of, 184-185, 672
Androgen blockade, for prostate cancer, after
Autologous blood donation, before radical
treatment failure, 409-410
prostatectomy, 365
Androgen deprivation therapy, for prostate
Autologous bone marrow transplant, for
cancer, 345, 353-354
neuroblastoma, &86
after treatment failure, 406
for prostatic adenocarcinoma, 197-198 Autosomal dominant polycystic kidney disease, in
children, 161
Androgen receptor genes, in prostate cancer, 211
Autosomal recessive polycystic kidney disease, in
Angiography, digital subtraction, of renovascular
children, 160-161
hypertension, 15
magnetic resonance, of renovascular
hypertension, 15-16 B
Bacille Calmette-Guerin, for bladder cancer,
Angiomas, retinal, von Hippel- Lindau disease
768-769
and, 131
failure of, 771-772
Angiomyolipomas, imaging of, 506-507
Balanitis xerotica obliterans, and squamous penile
tuberous sclerosis complex and, 837
carcinoma, 853
Angioplasty, percutaneous transluminal renal,
Bardet-Biedl syndrome, in children, 161
for ischemic nephropathy, 18-19
for renovascular hypertension, 17 Bax, as marker, for renal cell carcinoma, 456-457
Anthracyclines, for Wilms’ tumor, complications bel-2, as marker. for renal cell carcinoma,
of, 871 456-457, 492
Antiandrogen therapy, for prostate cancer, after Benign prostatic hyperplasia. prostate-specific
treatment failure, 408, 759-760 antigen in, 223, 267-268
physical burden of, 307
Bexarotene, for renal cell carcinoma, 606
Antibody imaging. of prostate cancer, 288
BHD gene, in renal cell carcinoma, 449
after treatment failure, 393. 394
Bicalutamide, for prostate cancer, after treatment
Antigens, in renal cell carcinoma, 460-462
monoclonal antibodies and, 626 failure, 408, 759-760
Bile acid absorption, after urinary tract
Antioxidants, in prevention, of prostate cancer,
230, 231 reconstruction, for recurrent bladder cancer.
784
Antiphospholipid antibody syndrome, and
thromboembolic disease, 57 Biopsy, of lymph nodes, for prostatic
adenocarcinoma, 192
Antitumor immune response, in renal cell of prostate cancer, 253-262,280-281
carcinoma, 428-430 after treatment failure, 392-393, 753
Apomorphine, for erectile dysfunction, 7 artificial neural networks and, 254-255
complications of, 260-261
Arteriography, of renovascular hypertension, 15
Gleason grade and, 259, 260
pharmacologic, of erectile dysfunction, 21
pathology and, 255-256
Artificial neural networks, and biopsy. of prostate prostate-specific antigen parameters and,
cancer, 254-255 253-254
prostate volume and, 256-257
Ascending pathways. in micturition, 28
technique for, 257-258
Asphyxiating thoracic dysplasia, in children, 163 when to stop, 258-260
Cumulative Index | Urol Clin N Am 30 (2003) 891-915 893
of prostatic fossa, after radical prostatectomy, Bones, involvement of, by recurrent seminoma,
712 808
by renal cell carcinoma, 845, 850
Birt-Hogg-Dube syndrome, and renal cell
carcinoma, 137, 446-447, 449-450 Bosniak classification, of cystic renal masses,
genetics of, 835-836 507-511
Bladder cancer, 765-776 Botanicals, for prostate cancer, 370, 372
extravesical recurrence of, 769-771
Bowel dysfunction, prostate cancer treatment
positive urine cytology and no
and, 310-311
demonstrable disease in, 770-771
prostatic urethral disease, 770 Bowenoid papulosis, and squamous penile
refractory, intravesical therapy for, 771-772 carcinoma, 854-855
radical cystectomy for, 772
Brachytherapy, interstitial. See Interstitial
upper tract disease, 767-770
brachytherapy.
intravesical therapy for, 768-769
nonurologic medications and, 127 Brain, involvement of, by renal cell carcinoma,
recurrent, 777-789 845, 849
distant, 778-779
Brain-imaging studies, in neurologic diseases, 32
local, 777-778
upper tract, 779-781 Brain stem, function of, in micturition, 28
management of, 780-781 Branchio-oto-renal syndrome, in children, 162
natural history of, 779
risk of, 779-780 Bromocriptine, for hyperprolactinemia, 76
surveillance of, 780
urethral, 770, 781-784 Cc
management of, 782-784 Capecitabine, for renal cell carcinoma, 602. 604
natural history of, 781-782
Captopril renogram, in renovascular
risk of, 782
hypertension, 15
surveillance of, 783
urinary tract reconstruction for, Carbergoline. for hyperprolactinemia, 76
complications of, 784-785
Carcinoembryonic antigen, as marker, for renal
restaging transurethral resection of, 767-768
cell carcinoma, 492
transurethral evaluation and resection of,
766-767 Carcinoma in situ, and squamous penile
tumor types in, 765-766 carcinoma, 855
in AIDS, 103
Bladder dysfunction, tuberculosis and, 112
Cardiac complications, of management, of
Bladder emptying, disorders of, nonurologic
Wilms’ tumor, 870-871
medications and, 122
Cardiovascular assessment, before radical
Bladder exstrophy, and male infertility, 148
prostatectomy, 364
Bladder filling. disorders of, nonurologic
CD44, as marker, for renal cell carcinoma, 460
medications and, 122-123
Central nervous system, recurrent
Bladder tumor antigen test, for recurrent
nonseminomatous tumors of, 827
transitional cell carcinoma, 796
recurrent seminoma of, 808
Blood glucose control, for diabetes mellitus, 3-4
Cerebral centers, in micturition, 28-29
Body composition, in prostate cancer, 213
Cerebrohepatorenal syndrome, in children, 166
Bone marrow transplant, for neuroblastoma, 886
Cerebrovascular disease. See Neurologic diseases.
Bone scans, of prostate cancer, after radical
CHARGE syndrome, in children, 162
prostatectomy, 710-711
after treatment failure, 754 Chemoprevention, of prostate cancer, 227-237
894 Cumulative Index Urol Clin N Am 30 (2003) 891-915
Chemoprevention (continued ) Clear cell sarcoma, renal, prognosis for. 874
antioxidants in, 230, 231 recurrent, 877
COX-2 inhibitors in, 233-234
Colic. tuberculosis and, 111-112
hormones in, 232
Prostate Cancer Prevention Trial in. Collagenous micronodules, in prostatic
232-233 adenocarcinoma, 190
risk factors and, 227-230
Collecting duct carcinoma, genetics of,
age, 228
426, 443
ethnicity, 228
nuclear morphometry of. 474-475
family history, 228-229
prognosis for, 488
genetics, 229
insulin-like growth factor-1, 230 Colloid carcinoma, of prostate, histology of.
prostate-specific antigen level, 228 195-196
serum factors, 229-230
Colorectal cancer, genitourinary involvement by.
SELECT in, 232 63-65
selenium in, 230-231
vitamin E in, 231 Comedocarcinoma, Gleason grade in, 188
Chemotherapy. for bladder cancer, 769 Complementary and alternative medicine, for
for leukemia, urologic complications of, 5 prostate cancer, 333, 369-376,690
for neuroblastoma, 886 acupuncture in, 37
surgery after, 885 botanicals in, 370, 372
for nonseminomatous tumors, 821-822 detoxification in, 371—372
for prostate cancer, after radical diets in, 371
prostatectomy, 716-717 for symptom control, 373
after treatment failure, 411 high-dose vitamins in, 371
for recurrent bladder cancer. 781 laetrile in, 372
for recurrent nonseminomatous tumors. metabolic therapies in, 371-372
825-826 PC-SPES in, 370
for recurrent seminomas, 805-808 prevalence of, 369-370
for renal cell carcinoma, 601-609 vitamin E in, 374
chemoimmunotherapy in, 603-605 Complex adherin, as marker, for renal cell
combination, 602-603 carcinoma, 457-458
retinoids in, 605-606
single-agent. 602 Computed tomography, of angiomyolipomas.
for seminomas, complications of, 810-811 506-507, 837
recurrence after, 808-809 of hereditary papillary renal cell
for squamous penile carcinoma, 860-861 carcinoma, 834
for tuberculosis. 118 of nonseminomatous tumors. 820
for Wilms’ tumor, 876 of prostate cancer, 285-286
complications of, 871 after radical prostatectomy. 711
after treatment failure, 394-395
Chromophobe renal cell carcinoma. genetics of, r recurrent transitional cell carcinoma, 796
426, 442-443 ‘renal cell carcinoma, 502-503
prognosis for, 487-488 technique for, 499-500
Chromosomal abnormalities, in male infertility, Condyloma acuminatum, and squamous penile
142-145 carcinoma, 854
Chromosome 3 translocations, and renal cell Congenital adrenal hyperplasia. and male
carcinoma, 448 infertility, 83-84
Ciliary dyskinesia, and male infertility, 148 Congenital bilateral absence of vas deferens, and
Clear cell carcinoma, genetics of, 425-426. male infertility, 145, 154-155
441-442. 448. 838
COX-2 inhibitors, in prevention, of prostate
prognosis for, 487 cancer, 233-234
Cumulative Index | Urol Clin V Am 30 (2003) 891-915 895
Crohn's disease. See Gastrointestinal disorders, Cyproterone acetate, for prostate cancer, after
inflammatory bowel disease. treatment failure, 408
Cryotherapy, for prostate cancer, 725-736 Cystadenomas, epididymal. von Hippel-Lindau
after treatment failure, 756 disease and, 154
anatomic issues in, 728
Cystectomy, bladder cancer after. See Bladder
and impotence, 730
cancer, recurrent.
and incontinence, 730-731
and pelvic and rectal pain, 731 Cystic fibrosis, and male infertility. 145-146,
and penile numbness, 731 154-155
and rectourethral fistula, 731—-732 and urolithiasis, 93-94
and tissue sloughing, 731
Cystic masses, renal, classification of, 507-511
and urethral stricture, 732
imaging of, 507-511
controversies in, 733-735
pseudoenhancement of, 511
equipment for, 727
factors affecting, 726-727 Cystitis, hemorrhagic, chemotherapy and, 56
failure of. treatment options after, 733 tuberculosis and. 112
follow-up of, 730
Cystometry. in neurologic diseases, 31
future trends in, 733-735
historical aspects of, 725-726 Cystopathy. diabetic. See Diabetes mellitus.
lymph node dissection with, 728 Cysts, pancreatic, von Hippel Lindau disease
mechanism of ablation by, 726 and, 132-133
neoadjuvant hormonal therapy with, 728 renal, tuberous sclerosis complex and, 837
patient selection for, 727-728
postoperative care for, 730 Cytadren, for prostate cancer, after treatment
failure, 409
preoperative preparation for, 728-729
prostate-specific antigen after, 730, 732-733 Cytokine-based therapy. for metastatic renal cell
results of, 732-733 carcinoma, 589-600,61 2
technique for, 729-730 adjuvant immunotherapy in, 5
tumor histology and, 728 adoptive immunotherapy in,
for recurrent prostate cancer, after interstitial combination therapy in, 592
brachytherapy. 746 interferons in, 591-595, 612
for renal cell carcinoma, 565-569, 571, interleukins in, 590-595, 612
838-839 lymphokine-activated killer cells in, 594
clinical observations in, 567-568 rationale for, 589-590
contraindications to, 567 tumor-infiltrating lymphocytes in,
equipment for, 566 594-595
follow-up of. 569, 571
Cytology, of recurrent transitional cell carcinoma,
indications for, 566-567
796
pathophysiology of. 565 566
results of, 568-569 Cytoreductive surgery, for metastatic renal cell
technique for, 567 carcinoma, 548, 581-588
Phase II randomized trials on. 87
Cryptophthalmos syndrome, in children, 162
rationale for, 581-583
Cryptorchidism, and risk of seminomas, 812 retrospective single-institution series on,
583-585
Crystalloids. in prostatic adenocarcinoma.
189-190
Cushing’s syndrome, and male infertility, 87
D
Cutaneous horn, and squamous penile Dendritic cell-based tumor vaccines, for renal cell
carcinoma, 853 carcinoma. See Tumor vaccines.
Cyclins, as markers, for renal cell carcinoma, Depression, prostate cancer and, 298
Cyclophosphamide, and bladder cancer, 127 Detoxification, for prostate cancer, 371-372
896 Cumulative Index Urol Clin V Am 30 (2003) 891-915
Detrusor areflexia. cerebrovascular disease E
and, 37 Eagle-Barrett syndrome, and male infertility.
Parkinson's disease and parkinsonism and, 42 in children, 164
Detrusor contractility, impaired. cerebrovascular Efferent pathways. in micturition, 27—28
disease and, 37
Ehlers-Danlos syndrome. in children. 162
Detrusor hyperreflexia, cerebrovascular disease
Ejaculatory dysfunction, and male infertility, 148
and, 36
diabetes mellitus and, 84
Parkinson's disease and parkinsonism and,
in AIDS, 101
41-42
nonurologic medications and. 123, 126
Dexamethasone, for prostate cancer, after vascular surgery and, 22-23
treatment failure, 409
Electrolyte imbalance. after urinary tract
Diabetes mellitus, 1-12 reconstruction, for recurrent bladder cancer.
and cystopathy, 1-4 784
diagnosis of, 1-3
Electromyography. in neurologic diseases, 31
management of, 3-4
in Parkinson's disease and parkinsonism.
pathogenesis of, 3
39-40
and ejaculatory dysfunction, 84
and erectile dysfunction, 4-7, 85 Endocrinopathies, genetic. and male infertility.
diagnosis of, 5 146-147
management of, 6—7
Endometrioid carcinoma, of prostate, histology
pathogenesis of, 5-6
of. 194-195
and male infertility, 84-85
and spermatogenesis, 84-85 Endoscopic surgery. for recurrent bladder cancer.
780-781
Dietary factors, in prostate cancer, 212-213.
for recurrent transitional cell carcinoma.
670-671
794-795
Diethylstilbestrol, for prostate cancer. after in surveillance. of recurrent transitional cell
treatment failure, 407 carcinoma, 798-799
Digital rectal examination, of prostate cancer. Endothelin-1. for prostate cancer. after radical
after radical prostatectomy. 709 prostatectomy, 717
after treatment failure, 393
Energy factors. in prostate cancer, 213
of recurrent prostate cancer, 699
Enteric hyperoxaluria, management of. 67-68
Digital subtraction angiography. of renovascular
hypertension, 15 Environmental factors, in prostate cancer.
912-214
Diverticulitis, urologic complications of, 65-66
Epididymal cystadenomas, von Hippel-Lindau
DNA alterations, in epithelial renal tumors,
disease and. 154
438 441
Epididymitis. nonurologic medications and, 127
DNA ploidy. in renal cell carcinoma, 472-473, 491
Erectile dysfunction, androgen abnormalities and.
Doppler ultrasonography, of prostate cancer,
OFnRe II= SOe 71-79
chemically induced, 75
DOX, for Wilms’ tumor, complications of, 871 hypogonadism, 71~75
testosterone preparations for, 73 75
Doxorubicin, for renal cell carcinoma, 603
diabetes mellitus and. See Diabetes mellitus.
Ductal carcinoma, of prostate. histology of, diagnosis of, 20-21
194-195 growth hormone deficiency and. 76
Duplex ultrasonography, of erectile dysfunction. in AIDS, 101
20-21 interstitial brachytherapy and, 357~—359
of renovascular hypertension, 15 lipid disorders and. 76
Cumulative Index Urol Clin V Am 30 (2003) 891-915
nonurologic medications and, 123 urinary, partial nephrectomy and, 536
prolactinomas and, 75-76
Floxuridine, for renal cell carcinoma, 602
radical pelvic surgery and, 66-67
radical prostatectomy and, 367 Fluoropyrimidines, for renal cell carcinoma, 602,
thyroid disease and. 76 604
vascular surgery and, 22-23
5-Fluorouracil. for renal cell carcinoma, 603, 604
Estrogen therapy, for prostate cancer. after
Flutamide, for prostate cancer, after treatment
treatment failure, 406-407
failure, 408
Exisulind, for prostate cancer, after radical
Foamy gland carcinoma, of prostate, diagnosis of,
prostatectomy. 717
196
External beam radiation therapy. See also
Folinic acid. for renal cell carcinoma, 603
Radiation oncology.
for prostate cancer, and sexual dysfunction, Follicle-stimulating hormone, disorders of, and
309 male infertility. 147
and urinary dysfunction, 310
Fraser syndrome, in children, 162
failure of, secondary treatment of.
See Prostate cancer, secondary Fuhrman grading system. for renal cell
treatment of. carcinoma, 472. 486
in favorable-risk patient, 339-342
in high-risk patient, 344-345 G
in intermediate-risk patient, 342-344 G250 antigens, in renal cell carcinoma, 462
interstitial brachytherapy after, 738-740
G250 monoclonal antibody, as marker, for renal
for squamous penile carcinoma, cell carcinoma, 457, 492-493
856-857
as therapy. for renal cell carcinoma, 626-629
Extraprostatic extension, of prostatic Gastrointestinal complications, of radiation
adenocarcinoma, 191-192 therapy. for prostate cancer, 324
Gastrointestinal disorders, 61-70
F colorectal cancer, 63-65
Factor V Leiden mutation, and thromboembolic diverticulitis. 65-66
disease. 57 inflammatory bowel disease, 61-63
and urolithiasis, 92-93
Fat, dietary. and prostate cancer. 671
fistulas in, 62-63
FDG-PET imaging, of recurrent seminomas, postoperative complications in, 63
808-809 ureteral obstruction in, 61-62
nephrolithiasis, 67-68
Female stress urinary incontinence, Parkinson's
pelvic surgery for. and erectile dysfunction,
disease and parkinsonism and, 42
66-67
Fertility, after treatment, for seminomas, 811 and vesicourethral dysfunction, 66
in AIDS, 101-102 and voiding dysfunction, 66
Fetal face syndrome, in children. 164-165 Gemcitabine, for renal cell carcinoma, 603
Finasteride, for prostate cancer, after treatment Gene therapy. for diabetes mellitus, 4
failure, 408-409
Genetic disorders, and male infertility. See Male
in prevention, of prostate cancer, 232
infertility.
Fistulas, inflammatory bowel disease and. in children, 159-167
62-63 Aarskog syndrome, 160
rectal, interstitial brachytherapy and, 357 Alport’s syndrome, 160
rectourethral, after cryotherapy, for prostate autosomal dominant polycystic kidney
cancer, 731-732 disease, 161
retroperitoneal, nonurologic medications and. autosomal recessive polycystic kidney
127 disease, 160-161
89S Cumulative Index | Urol Clin N Am 30 (2003) 891-915
Genetic disorders (continued ) Goserelin, for prostate cancer, after treatment
Bardet-Biedi syndrome, 161 failure, 407
branchio-oto-renal syndrome, 162
Gout, and urolithiasis, 93
CHARGE syndrome, 162
Ehlers-Danlos syndrome, 162 Graft-versus-tumor response, in allogeneic stem
evaluation of, 159-160 cell transplantation, for renal cell carcinoma,
Fraser syndrome, 162 618-620
Goldenhar syndrome, 162
Graves’ disease, and male infertility, 85-86
hypertelorism-hypospadias syndrome, 162
intersex disorders, 162-163 Gray-scale ultrasonography, of prostate cancer,
Jeune syndrome, 163 282-285
Lesch-Nyhan syndrome, 163 Growth factor deficiency, and erectile
Meckel-Gruber syndrome, 163 dysfunction, 76
Menkes disease, 163
MURCS syndrome, 163 Growth factors, in prostate cancer, 211-212
nail-patella syndrome, 163-164
Noonan syndrome, 164 iH
oculocerebrorenal syndrome of Lowe, 164 Head and neck, involvement of, by renal cell
Prader-Willi syndrome, 164 carcinoma, 849-850
prune-belly syndrome, 164
Hemangioblastomas, central nervous system,
Robinow syndrome, 164-165
von Hippel Lindau disease and, 131-132
sickle cell anemia, 165
Smith-Lemli-Opitz syndrome, 165 Hematologic diseases, 49-60
Turner syndrome, 165 leukemia, 55-56
VACTERL syndrome, 165 leukemic infiltration and tumor
Wilms’ tumor, 165-166 compression in, 55-56
Zellweger syndrome, 166 management of, urologic complications
of, 56
Genetic testing, for renal cell carcinoma, 449-450
priapism in, 55
Genistein, and lower risk, of prostate urolithiasis in, 55
cancer, 671 sickle cell anemia, 49-55, 151-152
and male infertility, 148
Genitourinary complications, of radiation
hematuria in, 50
therapy, 56
in children, 165
for prostate cancer, 324
inheritance patterns in, 49-50
Germ cell tumors. See Seminomas. nephropathies in, 50
Gleason grade, in prostate cancer, 187-189, 259, nephrotic syndrome in, 51-52
260, 264 papillary necrosis in, 50-51
after radical prostatectomy, 704, 706 priapism in, 53-55, 151, 165
after treatment failure, 391 proteinuria in, 51
and radical prostatectomy, 364, 365 renal failure in, 52
renal medullary carcinoma in, 53
Glomerular disease, after treatment, for Wilms’ renal tubular abnormalities in, 52
tumor, 871 testicular infarction in, 55
Glomeruloid pattern, in prostate cancer, 196 urinary tract infections in, 52-53
vesicular infections in, 55
Glucocorticoids, for prostate cancer, after
thromboembolic disease, 57-59
treatment failure, 409
antiphospholipid antibody syndrome in, 57
Goldenhar syndrome, in children, 162 Henoch-Schénlein purpura in, 58—59
hereditary hypercoagulable syndromes in, 57
Gonadal complications, of management, of
in neonates, 58
Wilms’ tumor, 872
in pregnancy, 57
Gonadotropin-releasing hormone, disorders of, membranous nephropathy and nephrotic
and male infertility, 146-147 syndrome in, 58
Cumulative Index | Urol Clin N Am 30 (2003) 891-915
neoplasms in, 57-58 Hyperoxaluria, and urolithiasis, 91-92
management of, 67-68
Hematospermia, prostate biopsy and, 261
Hyperparathyroidism, and urolithiasis, 90-91
Hematuria, prostate biopsy and, 260
sickle cell anemia and, 50 Hyperprolactinemia, and erectile dysfunction,
tuberculosis and, 111-112, 115-116 75-76
and male infertility, 86
Hemorrhagic cystitis, chemotherapy and, 56
Hypertelorism-hypospadias syndrome, in
Henoch-Schénlein syndrome, and
children, 162
thromboembolic disease, 58-59
Hyperthyroidism, and male infertility, 85-86
Hepatic complications, of management, of Wilms’
tumor, 871-872 Hyperuricemia, and urolithiasis, 93
High-intensity focused ultrasonography, Hypogonadism, and erectile dysfunction, 71~75
therapeutic, for renal cell carcinoma, 573-575 testosterone preparations for, 73-75
and male infertility, 82-84
HIV infection, condyloma acuminatum with, 854
genitourinary tuberculosis with, 111 Hypomethylation, in renal cell carcinoma, 440
Hormonal therapy, for prostate cancer, 692-699 Hyposthenuria, sickle cell anemia and, 52
after radical prostatectomy, 714-716
Hypothalamic-pituitary-testicular axis, in male
after treatment failure. See Prostate cancer,
infertility, 81
secondary treatment of.
and osteoporosis, 696-697 Hypothyroidism, and male infertility, 86
and sarcopenia, 697-698
and weight gain and obesity, 698
I
as adjuvant therapy, 693-694
Immune response, following laparoscopic radical
as neoadjuvant therapy, 694
nephrectomy, for renal cell carcinoma,
as primary therapy, 693
548. 549
cryotherapy with, 728
in renal cell carcinoma, 428-430
for metastatic disease, 695-696
for relapse, 694 ImmunoCyt test, for recurrent transitional cell
for stage T1-2 disease, 694-695 carcinoma, 796
for stage T3-4 disease, 695
Immunogenic tumor antigens, in renal cell
recurrence after, 698-699
carcinoma, 460
Hormone ablation therapy, for prostate cancer,
Immunotherapy. See a/so Allogeneic stem cell
physical burden of, 307
transplantation.
Hormones, in prevention, of prostate cancer, 232 adjuvant, for metastatic renal cell carcinoma,
in prostate cancer, 211-212 595
Hoxsey regimen, for prostate cancer, 372 adoptive, for metastatic renal cell carcinoma,
593-595
HPC] gene, in familial prostate cancer, 669-670 for recurrent bladder cancer, 781
HPC2 gene, in familial prostate cancer, 670 for renal cell carcinoma, molecular biology
and, 431-432
HPCX gene, in familial prostate cancer, 670
rationale for, 611-612
Human kallikrein-2, in prostate cancer, 268-269
Impotence, after cryotherapy, for prostate
versus prostate-specific antigen, 268-269
cancer, 730
Hydrocortisone, for prostate cancer, after Incontinence, after cryotherapy, for prostate
treatment failure, 409
cancer, 730-731
Hypercoagulable syndromes, and Indinavir, and nephrolithiasis, 99-100
thromboembolic disease, 57 and urolithiasis, 95, 127
Hypermethylation, in renal cell carcinoma, 431 Infections, in tuberculosis. See Tuberculosis.
900 Cumulative Index | Urol Clin N Am 30 (2003) 891-915
Infections (continued) results of, 355, 738-740
prostate biopsy and, 260 software in, 352-353
urologic, in AIDS, 103-105 technique for, 354
for squamous penile carcinoma, 857
Infertility, male. See Male infertility.
Intracavernous injection and self-stimulation test.
Inflammatory bowel disease. See Gastrointestinal
for erectile dysfunction, 20
disorders.
Intracavernous injections, of vasoactive agents,
Inguinal lymph nodes, in squamous penile
for erectile dysfunction, 6—7
carcinoma, 858, 862-863
Intracavitary photon radiation therapy, for renal
Insulin-like growth factor-1, in prostate cancer,
cell carcinoma, 575, 577
211-212, 230, 269
Intratubular germ cell neoplasia. and risk of
Intensity-modulated radiation therapy, for
seminomas, 811-812
prostate cancer, 341-343
Intravesical therapy, for bladder cancer, 768-769,
Interferons, for metastatic renal cell carcinoma,
771-772
590-595. 603-606, 612
Irritative voiding symptoms, interstitial
Interleukins, for metastatic renal cell carcinoma,
brachytherapy and, 357
590-595. 612
in prostate cancer, 271-272 Ischemic nephropathy. See Vascular disease.
Intersex disorders. in children, 162-163 Isotretinoin, for renal cell carcinoma, 605-606
Interstitial brachytherapy. See also Radiation
oncology. J
for prostate cancer, 351-362, 737-750 Jeune syndrome, in children, 163
after treatment failure, 756-757
and bowel dysfunction, 311
k
and quality of life, 359
Kallmann syndrome, and male infertility, 146
and sexual dysfunction, 309
and urinary dysfunction, 310 Kaposi's sarcoma, in AIDS, 102-103
dosimetry in, 354-355
Kartagener syndrome, and male infertility, 148
failure of, secondary treatment of. See
Prostate cancer, secondary Karyometric markers, for renal cell carcinoma.
treatment of. 460
follow-up of, 740-742 Kennedy's disease, and male infertility, 147, 156
biopsy in, 742
physical examination in, 741-742 Ketoconazole, for prostate cancer, after treatment
post-implant dosimetry. 740-741 failure, 409
prostate-specific antigen in, 742 Ki-67, as marker, for renal cell carcinoma, 457.
hardware in, 351-352 492
hormonal therapy with, 353-354
in favorable-risk patient, 339-342 Klinefelter syndrome, and male infertility, 82.
isotopes in, 738 144-145
morbidity in, 356-359
patient selection for, 353 L
prostate-specific antigen after, 742 Laetrile, for prostate cancer, 372
recurrent disease after, 742-743
Laparoscopic nephroureterectomy,. for recurrent
salvage cryotherapy for. 746
transitional cell carcinoma, 793-794
salvage radiation therapy for, 745-746
salvage radical. prostatectomy for, Laparoscopic partial nephrectomy, for renal cell
744-745 carcinoma, 551, 553-563, 565
staging and risk stratification of, complications of, 559-561
743-744 contraindications to, 551, 553